EMA/ Payer meeting on evidence generation along the life-cycle of medicinal products

Health care Payers and the European Medicines Agency met on 12 March 2021 to discuss synergies and cultivate mutual understanding and cooperation on evidence generation along the life-cycle of medicinal products. Addressing gaps in evidence generation is particularly important when it comes to highly innovative technologies, as these often come with a higher level of uncertainty regarding safety and effectiveness at the point of market entry. The meeting was an opportunity for the participants to share experiences and perspectives on evidence generation, identify evidence gaps and discuss the challenges surrounding the use of registries and routine data as sources for RWD for post-marketing authorisation.

INAMI-RIZIV was represented by Marc Van De Casteele. His presentation about RWE4Decisions is made available here.